Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis
Authors:
Open Access
- 22 July 2022
- journal article
- research article
- Published by Medknow in Journal of Family Medicine and Primary Care
- Vol. 11 (7) , 3693-3698
Abstract
Introduction: Remdesivir, an antiviral drug, received an emergency use authorization for treating coronavirus disease 2019 (COVID-19) patients. Though many studies have reported the safety aspects of this antiviral agent, most of them were observed in severely ill COVID-19 patients, making very less data available in the moderately ill patients. The present study was conducted with an objective of finding the adverse events (AEs) associated with remdesivir in moderately ill COVID-19 patients. Methodology: A retrospective observational study was conducted by collecting data of demographic details and details of remdesivir, laboratory investigations, and AEs from the patient medical records from May to July 2021 and analyzed by using the appropriate statistics. Results: Out of the 160 COVID-19 patients, 32 were moderately ill (males: 29, females: 03) and were treated with remdesivir along with steroids and low molecular weight heparin (LMW) heparin. The average number of administered remdesivir doses was 4, with a loading dose of 200 mg and a maintenance dose of 100 mg. A total of 41 AEs were observed out of which 17 were adverse drug reactions (ADRs) (a significant increase in the alanine transaminase (ALT) [P < 0.001]) and 23 AEs (a significant rise in random blood sugars, RBS [one of the AEs] [P = 0.007]). The AEs were more commonly seen in the hypertensive patients. An increased oxygen requirement was a major serious AE observed in four patients. Conclusion: Remdesivir caused a significant increase in the liver enzymes. Increased blood sugar levels were the most common AE and increased oxygen requirement was the major serious AE observed.Keywords
This publication has 20 references indexed in Scilit:
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Safety profile of the antiviral drug remdesivir: An updateBiomedicine & Pharmacotherapy, 2020
- Liver injury in remdesivir-treated COVID-19 patientsHepatology International, 2020
- COVID-19 infection: Emergence, transmission, and characteristics of human coronavirusesJournal of Advanced Research, 2020
- Compassionate Use of Remdesivir for Patients with Severe Covid-19New England Journal of Medicine, 2020
- Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the SameDrug Safety, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- StatPearls2020
- Factors affecting the development of adverse drug reactions (Review article)Saudi Pharmaceutical Journal, 2014
- LiverTox: Clinical and Research Information on Drug-Induced Liver Injury2012